- £218.75bn
- £236.77bn
- $54.07bn
- 78
- 14
- 98
- 73
REG - AstraZeneca PLC - Calquence approved in Japan for CLL
AnnouncementREG - AstraZeneca PLC - Calquence met primary endpoint against ibrutinib
AnnouncementREG - AstraZeneca PLC - Enhertu approved in the EU for breast cancer
AnnouncementREG - AstraZeneca PLC - Enhertu approved in the US for gastric cancer
AnnouncementREG - Jupiter Asset Mgmnt - Portfolio Update
AnnouncementREG - AstraZeneca PLC - Imfinzi new dosing approved in EU
AnnouncementREG - AstraZeneca PLC - Farxiga granted US Priority Review for CKD
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Atacand divestment in over 70 countries completed
AnnouncementREG - AstraZeneca PLC - AstraZeneca’s COVID-19 vaccine authorised in UK
AnnouncementREG - AstraZeneca PLC - Lynparza approved in Japan for three cancers
AnnouncementREG - AstraZeneca PLC - Tagrisso approved in the US for early lung cancer
AnnouncementREG - AstraZeneca PLC - Update on US regulatory review of roxadustat
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - Jupiter Asset Mgmnt - Portfolio Update
AnnouncementREG - AstraZeneca PLC - Imfinzi new dose receives positive EU CHMP opinion
AnnouncementREG - AstraZeneca PLC - Trixeo Aerosphere approved in the EU for COPD
AnnouncementREG - AstraZeneca PLC - Trastuzumab deruxtecan positive CHMP
Announcement